Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma

@article{Duerinck2016RandomizedPI,
  title={Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma},
  author={Johnny Duerinck and Stephanie Du Four and Fenne Vandervorst and Nicky D’Haene and Marie Le Mercier and Alex Michotte and A. M. Van Binst and Hendrik Everaert and Isabelle Salmon and Frank Bouttens and Vincent Verschaeve and Bart Neyns},
  journal={Journal of Neuro-Oncology},
  year={2016},
  volume={128},
  pages={147-155}
}
We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide. Forty-four patients were randomly assigned to receive treatment with axitinib (5 mg BID starting dose; N = 22) or “physicians best… CONTINUE READING